Our Clinical Pipeline

Currently, four Inhibrx programs are in ongoing Phase 1 clinical trials: three for the treatment of various cancers, and one for Alpha-1 Antitrypsin Deficiency (AATD).

The Candidates

Preclinical

Phase 1

Phase 2

Phase 3

INBRX-106

Our Hexavalent OX40 Agonist

Oncology

INBRX-106 is a hexavalent sdAb-based therapeutic candidate targeting OX40 currently being evaluated in patients with locally advanced or metastatic solid tumors. Signaling through OX40 provides co-stimulation that promotes T-cell expansion, enhanced effector function and memory cell formation, and prevents activation-induced cell death.

Learn more clinicaltrials.gov

INBRX-109

Our Tetravalent DR5 Agonist

Oncology

INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate that agonizes DR5 to induce tumor selective programmed cell death.

Learn more clinicaltrials.gov

INBRX-105

Our PD-L1 x 4-1BB Tetravalent Conditional Agonist

Oncology

INBRX-105 is a tetravalent sdAb-based therapeutic candidate currently being evaluated in patients with programmed death ligand 1 (PD-L1) expressing tumors, including those refractory to, or relapsed from, approved checkpoint inhibitor therapies. INBRX-105 is designed to agonize 4-1BB selectively in the presence of PD-L1.

Learn more clinicaltrials.gov

INBRX-101

Our Recombinant Alpha-1 Anti- trypsin Fc-Fusion Protein (AAT-Fc)

Orphan / Respiratory

INBRX-101 is a recombinant human AAT-Fc fusion protein therapeutic candidate currently being evaluated for the treatment of AATD. Early clinical data has demonstrated a promising pharmacokinetic profile that we believe supports a dosing schedule of every three weeks to achieve continuous normal AAT serum concentrations, a significant improvement from patients’ current regimen.

Learn more clinicaltrials.gov